162 related articles for article (PubMed ID: 18714847)
1. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain.
Annemans L; Caekelbergh K; Morlion B; Hans G; De Cock P; Marbaix S
Acta Clin Belg; 2008; 63(3):170-8. PubMed ID: 18714847
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
[TBL] [Abstract][Full Text] [Related]
3. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
4. A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting.
Prettyjohns M; Sandelin R; Lister S; Norrefalk JR
J Med Econ; 2012; 15(6):1097-109. PubMed ID: 22712872
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; Rejas J
Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
10. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.
Gordon J; Lister S; Prettyjohns M; McEwan P; Tetlow A; Gabriel Z
J Med Econ; 2012; 15(2):207-18. PubMed ID: 22017236
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
Ritchie M; Liedgens H; Nuijten M
Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
[TBL] [Abstract][Full Text] [Related]
12. Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.
Pérez C; Navarro A; Saldaña MT; Figueras-Balsells M; Muñoz-Tudurí M; Rejas J
Clin J Pain; 2013 Jun; 29(6):471-7. PubMed ID: 23328322
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
[TBL] [Abstract][Full Text] [Related]
15. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
Bellows BK; Dahal A; Jiao T; Biskupiak J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
[TBL] [Abstract][Full Text] [Related]
16. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
17. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Mar; 12(3):209-18. PubMed ID: 21676163
[TBL] [Abstract][Full Text] [Related]
18. A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics.
Morera-Domínguez C; Ceberio-Balda F; Flórez-García M; Masramón X; López-Gómez V
Clin Drug Investig; 2010; 30(8):517-31. PubMed ID: 20513162
[TBL] [Abstract][Full Text] [Related]
19. PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial.
Mathieson S; Maher CG; McLachlan AJ; Latimer J; Koes BW; Hancock MJ; Harris I; Day RO; Pik J; Jan S; Billot L; Lin CW
Trials; 2013 Jul; 14():213. PubMed ID: 23845078
[TBL] [Abstract][Full Text] [Related]
20. Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics.
Flórez-García M; Ceberio-Balda F; Morera-Domínguez C; Masramón X; Pérez M
Pain Pract; 2011; 11(4):369-80. PubMed ID: 21199310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
